Unable to find a retooled deal pleasing to both sides, ImmunoGen Inc. and GlaxoSmithKline plc - which earlier said they were striving to do so - have ended their development agreement for cantuzumab mertansine (huC242-DM1). (BioWorld Today)
Some cynical Europeans might snicker about industry in America profiting from a threatened terrorist siege. Other commentators may marvel instead at company scientists' ability to engineer biodefense weapons. The editorial-page beat goes on.
Spurning an eleventh-hour suitor that made an offer last week, diagnostic testing firm Variagenics Inc. said its board wants to go ahead with the previously planned merger with Hyseq Inc. (BioWorld Today)
Look up the origins of the word "enzyme" in the dictionary and you'll find it has a possible Greek root, related to the word "juice." Look up "juice," and you'll find that it can be defined as "strength, vigor, vitality" - words seldom associated with the biotechnology sector these days. (BioWorld Financial Watch)
